ASPHF (Ascentage Pharma Group International) Other Current Assets: $21.30 Mil (As of Dec. 2025)


ASPHF Ascentage Pharma Group International ASPHF
71 GF Score
Price $4.53
GF Value $6.61
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International Other Current Assets?

Ascentage Pharma Group International ASPHF -3.51% 71 Other Current Assets is $21.30 Mil as of Dec. 2025. GuruFocus rates ASPHF with a GF Score™ of 71/100 and a GF Value™ of $6.61 (Possible Value Trap). The stock has 7 warning signs investors should review.

Ascentage Pharma Group International's other current assets for the quarter that ended in Dec. 2025 was $21.30 Mil.

Ascentage Pharma Group International's quarterly other current assets declined from Dec. 2024 ($18.12 Mil) to Jun. 2025 ($0.00 Mil) but then increased from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($21.30Mil).

Ascentage Pharma Group International's annual other current assets increased from Dec. 2023 ($13.33 Mil) to Dec. 2024 ($18.12 Mil) increased from Dec. 2024 ($18.12 Mil) to Dec. 2025 ($21.30 Mil).


Ascentage Pharma Group International Other Current Assets Related Terms


Ascentage Pharma Group International Other Current Assets Historical Data

* Premium members only.

The historical data trend for Ascentage Pharma Group International's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International Other Current Assets Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.39 12.90 13.33 18.12 21.30

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.33 0.00 18.12 0.00 21.30
ASPHF
71GF Score
Ascentage Pharma Group International ASPHF
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascentage Pharma Group International Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $21.30 Mil mean?
Ascentage Pharma Group International (ASPHF) has a Other Current Assets of $21.30 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Ascentage Pharma Group International.
Is Ascentage Pharma Group International's Other Current Assets too high?
Ascentage Pharma Group International's current Other Current Assets is $21.30 Mil. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Other Current Assets compare to VRTX and REGN?
Ascentage Pharma Group International's Other Current Assets of $21.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Ascentage Pharma Group International. Ascentage Pharma Group International's current Other Current Assets is $21.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Other Current Assets is $21.30 Mil. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Other Current Assets is $21.30 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

  • Other Current Assets: $21.30 Mil
  • GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score

Get the complete analysis for ASPHF

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$6.61
GF Value